TABLE 3.

Kinetic properties of meropenem in CSF after i.v. administration of 2 g

Patient	Cmax (mg/liter)	Tmaxa (h)	AUC (mg · h/liter)	AUCCSFextrapolated/ AUCCSF (%)	t1/2β (h)	AUCCSF/ AUCS	Time (h) above a MIC of:		t*1/2CSF (h)
							0.125 μg/ml	0.5 μg/ml
1	1.60	2	14.2	16.1	5.65	0.067	16	9	2.18
2	1.22	4	17.2	33.1	8.55	0.056	16	11	5.68
3	1.09	4	18.3	30.3	7.79	0.089	16	13	8.46
4	0.65	7	14.7	43.7	11.9	0.063	16	12	10.66
5	0.48	4	4.46	9.8	4.57	0.049	15	0	4.63
6	0.41	10	5.80	14.7	6.46	0.043	13	0	8.61
7	0.29	2	4.87	30.6	8.31	0.037	14	0	7.87
8	0.24	2	2.27	14.1	5.30	0.023	8	0	4.78
9	0.20	2	1.18	4.2	3.31	0.019	3	0	2.16
10	0.13	4	2.54	44.4	11.8	0.028	3	0	12.47
Mean (SDb)	0.63 (0.50)	4.1 (2.6)	8.55 (6.73)	26.1 (16.4)	7.36 (2.89)	0.047 (0.022)	12 (5)	5 (6)	6.75 (3.44)
Median	0.45	4	5.34	23.4	7.13	0.046	14	0	6.77

^aT_max, time to maximum concentration. 

^bSD, standard deviation.